Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Prepaid Assets (2020 - 2025)

Tarsus Pharmaceuticals has reported Prepaid Assets over the past 6 years, most recently at $13.5 million for Q4 2025.

  • Quarterly results put Prepaid Assets at $13.5 million for Q4 2025, down 8.03% from a year ago — trailing twelve months through Dec 2025 was $13.5 million (down 8.03% YoY), and the annual figure for FY2025 was $13.5 million, down 8.03%.
  • Prepaid Assets for Q4 2025 was $13.5 million at Tarsus Pharmaceuticals, down from $21.7 million in the prior quarter.
  • Over the last five years, Prepaid Assets for TARS hit a ceiling of $29.2 million in Q2 2025 and a floor of $2.8 million in Q1 2021.
  • Median Prepaid Assets over the past 5 years was $5.5 million (2023), compared with a mean of $7.9 million.
  • Peak annual rise in Prepaid Assets hit 388.5% in 2025, while the deepest fall reached 11.82% in 2025.
  • Tarsus Pharmaceuticals' Prepaid Assets stood at $4.0 million in 2021, then increased by 17.85% to $4.8 million in 2022, then surged by 65.05% to $7.9 million in 2023, then soared by 86.2% to $14.6 million in 2024, then fell by 8.03% to $13.5 million in 2025.
  • The last three reported values for Prepaid Assets were $13.5 million (Q4 2025), $21.7 million (Q3 2025), and $29.2 million (Q2 2025) per Business Quant data.